Tarsus Pharmaceuticals, Inc.
Company Stats
- Market Cap
- $3.4B
- as of Sep 30, 2026
- Enterprise Value
- $3.3B
- Shares Outstanding
- 43.9M
- Free Float
- 79.3%
Income Statement
- Revenue
- $451.4M
- Operating Income
- -$71.0M
- Net Income
- -$66.4M
- EBITDA
- -$70.1M
- Revenue Growth, 3Y
- 159.5%
- FCF Margin, 3Y Avg
- -244.4%
- FCF Margin, Worst Year
- -682.0%
Cash Flow
- Free Cash Flow
- -$22.3M
- FCF Yield
- -0.6%
- Owner FCF Yield
- -1.9%
Balance Sheet
- Cash & Equivalents
- $183.6M
- Total Debt
- $75.0M
- Net Cash
- $108.6M
Returns & Capital
- SBC, 3Y Avg
- $29.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $451.4M | -$22.3M | -4.9% |
| FY2024 | $183.0M | -$84.6M | -46.2% |
| FY2023 | $17.4M | -$119.0M | -682.0% |
| FY2022 | $25.8M | -$49.5M | -191.9% |
| FY2021 | $57.0M | $3.2M | 5.5% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 14, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals to Expand Retina Pipeline